FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890102036> ?p ?o ?g. }

• W2890102036 endingPage "156" @default.
• W2890102036 startingPage "124" @default.
• W2890102036 abstract "BackgroundPsychiatric comorbidity is prevalent in persons with multiple sclerosis (MS). Few studies have assessed whether second-generation disease-modifying therapies (DMT) are associated with adverse psychiatric effects.ObjectiveWe aimed to systematically review the literature regarding the APEs associated with natalizumab, fingolimod, dimethyl fumarate, teriflunomide and alemtuzumab in MS. As a secondary objective, we evaluated changes in anxiety or depression scores following treatment with the aforementioned DMTs.MethodsWe searched MEDLINE, EMBASE, International Pharmaceutical Abstracts, PsychINFO, Central Register of Controlled Trials & Cochrane database of systematic reviews for published studies, and clinicaltrials.gov and regulatory documents from the US and Canada for unpublished studies. Data sources were searched from inception to September 2017. Studies reporting adverse psychiatric effects involving any DMT of interest were included. We report the incidence proportions of the adverse psychiatric effects and, where applicable, risk differences between DMT-exposed and unexposed individuals along with the corresponding 95% confidence intervals. We calculated the standardized mean differences (SMD) of changes in anxiety and depression scores if reported as study outcomes, and pooled the data using random effects meta-analysis.ResultsOf 4389 abstracts screened, 78 met the inclusion criteria, including 48 clinical trials, 28 observational studies and 2 case reports. Depression was the most commonly reported adverse psychiatric effect. Incidence proportions for all adverse psychiatric effects ranged from 0 to 24.7%. None of the DMT studied were associated with a statistically significant increased risk of any adverse psychiatric effect (range of risk difference: -7.69% [95%CI: -16.06%, 5.56%] to 6.67 [-8.56, 15.59]). Eighteen studies examined changes in depression or anxiety following fingolimod, natalizumab or dimethyl fumarate treatment; depression symptoms improved in fingolimod-treated groups (SMD [95%CI]: 1.18 [0.17, 2.19]). We did not identify studies examining changes in these outcomes following treatment with any of the other DMTs.ConclusionThe DMTs reviewed were not associated with an increased risk of adverse psychiatric effect in MS, and some may reduce the incidence of depressive symptoms. This may reflect either a positive direct effect (e.g. immune modulation) or an indirect effect arising due to a positive impact on disease activity or course." @default.
• W2890102036 created "2018-09-27" @default.
• W2890102036 creator A5012744052 @default.
• W2890102036 creator A5017585326 @default.
• W2890102036 creator A5022470998 @default.
• W2890102036 creator A5026882084 @default.
• W2890102036 creator A5033638129 @default.
• W2890102036 creator A5045908356 @default.
• W2890102036 creator A5063763659 @default.
• W2890102036 creator A5075948693 @default.
• W2890102036 creator A5077629436 @default.
• W2890102036 creator A5086059428 @default.
• W2890102036 date "2018-11-01" @default.
• W2890102036 modified "2023-10-18" @default.
• W2890102036 title "Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review" @default.
• W2890102036 cites W1242366555 @default.
• W2890102036 cites W1483881410 @default.
• W2890102036 cites W1666336517 @default.
• W2890102036 cites W1842142568 @default.
• W2890102036 cites W1871950814 @default.
• W2890102036 cites W1893794029 @default.
• W2890102036 cites W1923469918 @default.
• W2890102036 cites W1964464603 @default.
• W2890102036 cites W1967838438 @default.
• W2890102036 cites W1970190011 @default.
• W2890102036 cites W1971410270 @default.
• W2890102036 cites W1992656196 @default.
• W2890102036 cites W1996908089 @default.
• W2890102036 cites W1997947055 @default.
• W2890102036 cites W2002809692 @default.
• W2890102036 cites W2007125032 @default.
• W2890102036 cites W2012559245 @default.
• W2890102036 cites W2018809284 @default.
• W2890102036 cites W2018809310 @default.
• W2890102036 cites W2019582599 @default.
• W2890102036 cites W2036198637 @default.
• W2890102036 cites W2040559004 @default.
• W2890102036 cites W2040839813 @default.
• W2890102036 cites W2049871497 @default.
• W2890102036 cites W2074099214 @default.
• W2890102036 cites W2076772239 @default.
• W2890102036 cites W2089417699 @default.
• W2890102036 cites W2091283575 @default.
• W2890102036 cites W2096479500 @default.
• W2890102036 cites W2098923148 @default.
• W2890102036 cites W2103758700 @default.
• W2890102036 cites W2104948944 @default.
• W2890102036 cites W2105159132 @default.
• W2890102036 cites W2110153986 @default.
• W2890102036 cites W2118735809 @default.
• W2890102036 cites W2119579450 @default.
• W2890102036 cites W2124417387 @default.
• W2890102036 cites W2125435699 @default.
• W2890102036 cites W2128076015 @default.
• W2890102036 cites W2129967156 @default.
• W2890102036 cites W2131078277 @default.
• W2890102036 cites W2131709112 @default.
• W2890102036 cites W2133392888 @default.
• W2890102036 cites W2135746117 @default.
• W2890102036 cites W2137495383 @default.
• W2890102036 cites W2151340435 @default.
• W2890102036 cites W2155245449 @default.
• W2890102036 cites W2156268561 @default.
• W2890102036 cites W2156977089 @default.
• W2890102036 cites W2159712156 @default.
• W2890102036 cites W2160113268 @default.
• W2890102036 cites W2222225656 @default.
• W2890102036 cites W2267348707 @default.
• W2890102036 cites W2275389009 @default.
• W2890102036 cites W2305674326 @default.
• W2890102036 cites W2406225181 @default.
• W2890102036 cites W2416597160 @default.
• W2890102036 cites W2419281705 @default.
• W2890102036 cites W2507312414 @default.
• W2890102036 cites W2523042213 @default.
• W2890102036 cites W2538374410 @default.
• W2890102036 cites W2551979274 @default.
• W2890102036 cites W2557301233 @default.
• W2890102036 cites W2565336176 @default.
• W2890102036 cites W2735066313 @default.
• W2890102036 cites W2746558379 @default.
• W2890102036 cites W2751712578 @default.
• W2890102036 cites W2753924326 @default.
• W2890102036 cites W2754639988 @default.
• W2890102036 cites W2756171169 @default.
• W2890102036 doi "https://doi.org/10.1016/j.msard.2018.09.008" @default.
• W2890102036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30248593" @default.
• W2890102036 hasPublicationYear "2018" @default.
• W2890102036 type Work @default.
• W2890102036 sameAs 2890102036 @default.
• W2890102036 citedByCount "29" @default.
• W2890102036 countsByYear W28901020362019 @default.
• W2890102036 countsByYear W28901020362020 @default.
• W2890102036 countsByYear W28901020362021 @default.
• W2890102036 countsByYear W28901020362022 @default.
• W2890102036 countsByYear W28901020362023 @default.
• W2890102036 crossrefType "journal-article" @default.
• W2890102036 hasAuthorship W2890102036A5012744052 @default.

• next